Retraction: Questioning the HIV-AIDS hypothesis: 30 years of dissent (Frontiers in Public Health, (2014), 2, (154), 10.3389/fpubh.2014.00154);Questioning the HIV-AIDS hypothesis: 30 years of dissent

Frontiers in Public Health

Volumn 2, Issue SEP, 2014, Pages

  Goodson, Patricia ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

Author keywords

AIDS; Causation; Dissent; HIV; Multifactorial causality

Indexed keywords

EID: 84984887707     PISSN: None     EISSN: 22962565     Source Type: Journal    
DOI: 10.3389/fpubh.2019.00334     Document Type: Erratum

References (96)

1. Duesberg PH. Inventing the AIDS Virus. Washington, DC: Regnery Publishing, Inc (1996). 722 p.
2. Delborne JA. Transgene and transgressions: scientific dissent as heterogeneous practice. Soc Stud Sci (2008) 38(4):509-41. doi:10.1177/0306312708089716
3. Goodson P. Theory in Health Promotion Research and Practice: Thinking Outside the Box. Sudbury, MA: Jones & Bartlett Publishers (2010). 245 p.
4. Altman L. Federal Official Says He Believes Cause of AIDS has been Found. The NewYork Times (1984). 1 p.
5. The HJ Kaiser Family Foundation. HIV/AIDS at 30: A Public Opinion Perspective. A report based on the Kaiser Family Foundation's 2011 Survey of Americans on HIV/AIDS. Menlo Park, CA: The Kaiser Family Foundation (2011). Available from: www.kff.org
6. Altman L. New U.S. Report Names Virus that may Cause AIDS. The New York Times (1984). 1 p.
7. de Harven E. Human endogenous retroviruses and AIDS research: confusion, consensus, or science? J Am Phys Surg (2010) 15(3):69-74.
8. The Durban declaration. Nature (2000) 406:15-6. doi:10.1038/35017662
9. MartinR, JankovicD, GoelA, MuldersM, Dabbagh A, Khetsuriani N, et al. Vital signs: HIV prevention through care and treatment -United States. MMWR (2011) 60(47):1618-23.
10. Altman L. Red Cross Evaluates Test to Detect AIDS in Donated Blood. The New York Times (1984). Section C; Page 2, Column 1.
11. OraQuick. What is OraQuick? [Internet]. Available from: http://www.oraquick.com/What-is-Ora Quick
12. CDC. Antibodies to a retrovirus etiologically associated with acquired immunodeficiency syndrome (AIDS) in populations with increased incidences of the syndrome. MMWR (1984) 33(27):377-9.
13. Johnson C. Whose antibodies are they anyway? Continuum (1996) 4(3):4-5.
14. Farber C. Serious Adverse Events: An Uncensored HistoryofAIDS. Hoboken, NJ:MelvilleHouse Publishing (2006).
15. Center for Infectious Diseases, CDC. Current trends classification system for human Tlymphotropic virus type III/lymphadenopathyassociated virus infections. MMWR (1986) 35(20):334-9.
16. CDC. Perspectives in disease prevention and health promotion public health service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR (1987) 36(31):509-15.
17. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR (1987) 36(1S):3S-15S.
18. Bauer H. HIV tests are not HIV tests. J Am Phys Surg (2010) 15(1):05-09.
19. Papadopulos-Eleopulos E, Turner V, Papadimitriou J. Is a positive western blot proof of HIV infection? Biotechnology (1993) 11:696-707. doi: 10.1038/nbt0693-696
20. Gluschankof P, Mondor I, Gelderblom H, Sattentau Q. Cell membrane vesicles are a major contaminant of gradient-enriched human immunodeficiency virus type-1 preparations. Virology (1997) 230:125-33. doi:10.1006/viro.1997.8453
21. Helma J, Schmidthals K, Lux V, Nuske S, Scholz A, Krausslich H, et al. Direct and dynamic detection of HIV-1 in living cells. PLoS One (2012) 7(11):e50026. doi:10.1371/journal.pone.0050026
22. Bess J, Gorelick R, Bosche W, Henderson L, Arthur L. Mocrovesicles are a source of contaminating cellular proteins found in purified HIV-1 preparations. Virology (1997) 230:134-44. doi:10.1006/viro.1997.8499
23. de Harven E. Problems with Isolating HIV. [Internet]. Available from: http://www.altheal.org/isolation/isolhiv.htm
24. AIDS gov. What is Viral Load? [Internet]. Available from: http://www.aids.gov/hiv-aids-basics/just-di agnosed-with-hiv-aids/understand-your-test-resu lts/viral-load/
25. Dorak T. Real-Time PCR. New York, NY: Taylor & Francis (2006).
26. Sax P, Cohen C, Kuritzkes D. HIV Essentials. 6th ed. Burlington, MA: Jones & Bartlett Learning (2013).
27. Owens D, Holodniy M, Garber A, Scott J, Sonnad S, Moses L, et al. Polymerase chain reaction for the diagnosis of HIV infection in adults: a meta-analysis with recommendations for clinical practice and study design. Ann Intern Med (1996) 124(9):803-15. doi:10.7326/0003-4819-124-9-199605010-00004
28. Rodriguez B, Sethi A, Cheruvu V, Mackay W, Bosch R, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA (2006) 296(12):1498-506. doi:10.1001/jama.296.12.1498
29. Lauritsen J. Has Provincetown Become Protease Town? [Internet]. Available from: http://www. virusmyth.com/aids/hiv/jlprotease.html
30. Nelson P, Carnegie P, Martin J, Ejtehadi H, Hooley P, Roden D, et al. Demystified.. human endogenous retroviruses. Mol Pathol (2003) 56:11-8. doi:10.1136/mp.56.1.11
31. Singh SK. Endogenous retroviruses: suspects in the disease world. Future Microbiol (2007) 2(3):269-75. doi:10.2217/17460913.2.3.269
32. Culshaw R. Science Sold Out: Does HIV Really Cause AIDS? Berkeley, CA: North Atlantic Books (2007).
33. Dictionary.com. Electron-Microscope. [Internet]. Available from: http://dictionary.reference.com/browse/electron-microscope
34. Barre-Sinoussi F, Chermann J, Rey F, Nugeyre M, Chamaret S, Gruest J, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).Science (1983)220:20. doi:10.1126/science.6189183
35. Kremer H. The Silent Revolution in Cancer and AIDS Medicine. Xlibris Corporation (2008).
36. Tahi D. Between the lines: a critical analysis of Luc Montagnier's interview answers to Djamel Tahi by Eleni Eleopulos and colleagues. Continuum (1997) 5(2):36-46.
37. de Harven E, Friend C. Further electron microscope studies of a mouse leukemia induced by cell-free filtrates. J Cell Biol (1960) 7(4):747-52. doi:10.1083/jcb.7.4.747
38. Tahi D. Did Luc Montagnier discover HIV? "I repeat: we did not purify!" Continuum (1997) 5(2):31-5.
39. Papadopulos-Eleopulos E, Turner V, Papadimitriou J, Page B, Causer D. Questions regarding whether the recently reported particles are authentic HIV virions? (2006). Available from: http://www.theperthgroup.com/REJECTED/StructureLetterPG.pdf
40. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine (2013) 31:3502-18. doi:10.1016/j.vaccine.2013.05.018
41. Cohen M, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med (2011) 365(6):493-505. doi:10.1056/NEJMoa1105243
42. National Institute of Allergy and Infectious Diseases. Challenges in Designing HIV Vaccines. [Internet]. Available from: http://www.niaid.nih.gov/top ics/HIVAIDS/Understanding/Prevention/Pages/va ccineChalle
43. Lauritsen J. Poison by Prescription: The AZT Story. New York, NY: Asklepios (1990).
44. Engel J. The Epidemic: A Global History of AIDS. New York, NY: Smithsonian Books/Harper Collins (2006).
45. Null GAIDS. A Second Opinion. New York, NY: Seven Stories Press (2002).
46. Duesberg P, Koehnlein C, Rasnick D. The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition. J Biosci (2003) 28(4):383-412. doi:10. 1007/BF02705115
47. Alberts B. Science breakthroughs. Science (2011) 334:23. doi:10.1126/science.1217831
48. Cohen J. A powerful and perplexing new HIV prevention tool. Science (2010) 330:3. doi:10.1126/science.330.6009.1298
49. The Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet (2006) 368:451-8. doi:10.1016/S0140-6736(06) 69152-6
50. Moore P, Allen S, Sowell A, Van de Perre P, HuffD, Srufilira A, et al. Role of nutritional status and weight loss in HIV seroconversion among Rwandan women. J Acq Immun Def Synd (1993) 6: 611-6.
51. The Perth Group. HIV Infection -the Cause or Effect of Acquired Immune Deficiency? [Internet]. Available from: http://www.theperthgroup. com/REJECTED/AIDScausesHIV3.pdf
52. Payne BAI, Wilson IJ, Hateley CA, Horvath R, Santibanez-Koref M, Samuels DC, et al. Mitochondrial aging is accelerated by anti-retroviral therapy through the clonal expansion of mtDNA mutations. Nat Rev Genet (2011) 43(8):806-10. doi:10.1038/ng.863
53. Alberta Reappraising AIDS Society. Concerns about HAART (Highly Active Anti-Retroviral Therapy). [Internet]. Available from: http://aras.ab.ca/haart-ineffective.html
54. Martinez E, Milinkovic A, Buira E, de Lazzari E, Leon A, Larrousse M, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area. HIV Med (2007) 8:251-8. doi:10.1111/j.1468-1293.2007.00468.x
55. Zaunders JJ, Cunningham PH, Kelleher AD, Kaufman GR, JaramilloAB, Wright R, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T Lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis (1999) 180:320-9. doi:10.1086/314880
56. Valdiserri R. Thirty years of AIDS in America: a story of infinite hope. AIDS Educ Prev (2011) 23(6):479-94. doi:10.1521/aeap.2011.23.6. 479
57. Torian L, Chen M, Rhodes P, Hall I. HIV. Surveillance -United States, 1981-2008. MMWR (2011) 60(21):689-728.
58. UNAIDS. Fact Sheet -People Living with HIV. [Internet]. Available from: http://www.unaids. org/en/resources/campaigns/globalreport2013/factsheet/
59. Chin J. The AIDS Pandemic: The Collision of Epidemiology with Political Correctness. Oxford: Radcliffe Publishing (2007).
60. Root-Bernstein R. The Evolving Definition of AIDS. [Internet]. Available from: http://www.virusmyth. com/aids/hiv/rrbdef.html
61. Craven B, Stewart G. Economic implications of socio-cultural correlates of HIV/AIDS: an analysis of global data. Appl Econ (2013) 45:1789-800. doi:10.1080/00036846.2011.639737
62. Duesberg PH, Mandrioli D, McCormack A, Nicholson J, Rasnick D, Fiala C, et al. AIDS since 1984: no evidence for a new, viral epidemic -not even in Africa. Ital J Anat Embryo (2011) 116(2):73-92.
63. Kalichman S. Denying AIDS: Conspiracy Theories, Pseudoscience, and Human Tragedy. New York, NY: Copernicus Books; Springer (2009).
64. Sarngadharan M, Popovic M, Bruch L, Schupbach J, Gallo R. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science (1984) 224:4. doi:10.1126/science.6324345
65. Gallo R, Salahuddin S, Popovic M, Shearer G, Kaplan M, Haynes B, et al. Frequent detection and isolation of cytopathic retroviruses (HTLVIII) from patients with AIDS and at risk for AIDS. Science (1984) 224:4. doi:10.1126/science.6200936
66. Popovic M, Sarngadharan M, Read E, Gallo R. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 224:4. doi:10.1126/science.6200935
67. Schupbach J, Sarngadharan M, Gallo R. Antigens on HTLV-infected cells recognized by leukemia and AIDS sera are related to HTLV viral glycoprotein. Science (1984) 224:4. doi:10.1126/science. 6324349
68. Duesberg PH. Retroviruses as carcinogens and pathogens: expectations and reality. J Can Res (1987) 47:1199-220.
69. Duesberg PH. Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation. Proc Natl Acad Sci U S A (1989) 86:755-64. doi:10.1073/pnas.86.3.755
70. CDC. An evaluation of the immunotoxic potential of isobutyl nitrite. MMWR (1983) 64: 457-8.
71. Jaffe H, Choi K, Thomas P, Haverkos H, Auerbach D, Guinan M, et al. National case-control study of Kaposi's sarcoma and Pneumocystis carinii pneumonia in homosexual men: part 1,epidemiologic results. Ann Intern Med (1983) 99(2):145-51. doi:10.7326/0003-4819-99-2-145
72. Duesberg P, Rasnick D. The AIDS dilemma: drug diseases blamed on a passenger virus. Genetica (1998) 104:85-132. doi:10.1023/A:1003405220186
73. Bauer H. The Origin, Persistence and Failings of HIV/AIDS Theory. Jefferson, NC: McFarland & Company, Inc., Publishers (2007).
74. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci (2004) 75:639-53. doi: 10.1016/j.lfs.2003.10.042
75. Lechner M, Lirk P, Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol (2005) 15:277-89. doi:10.1016/j.semcancer.2005. 04.004
76. Watson JD. Type 2 diabetes as a redox disease. Lancet (2014) 383:841-43. doi:10.1016/S0140-6736(13)62365-X
77. Papadopulos-Eleopulos E, Turner V, Papadimitriou J. Oxidative stress, HIV and AIDS. Res Immunol (1992) 143:145-8. doi:10.1016/S0923-2494(92)80156-F
78. Gougeon M, Montagnier L. Apoptosis in AIDS. Science (1993) 260:28. doi:10.1126/science. 8098552
79. Papadopulos-Eleopulos E, Turner V, Papadimitriou J, Causer D, Hedland-Thomas B, Page B. A critical analysis of the HIV-T4-cell-AIDS hypothesis. In: Duesberg P, editor. AIDS: Virus-or Drug Induced? Kluwer Academic Publishers (1996). p. 3-22. Available from: 10.1007/978-94-009-1651-7_1
80. Mullis K. A hypothetical disease of the immune system that may bear some relation to the acquired immune deficiency syndrome. Genetica (1995) 95:195-7. doi:10.1007/BF01435010
81. AIDS gov. Overview of HIV Treatments. [Internet]. Available from: http://aids.gov/hiv-aids-basics/just-diagnosed-with-hiv-aids/treatment-options/overview-of-hiv-treatments/index.html
82. Green H, Paul M, Vidal L, Leibovic L. Prophylaxis of Pneumocystis pneumonia in Immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. May Clin Proc (2007) 82(9):1052-9. doi:10.4065/82.9.1052
83. Giraldo R. "Co-factors" Cause AIDS. [Internet]. Available from: http://www.robertogiraldo.com/eng/papers/CoFactorsCauseAIDS.html
84. Sonnabend J. Letter to the editor. Lancet (2000) 355:2163.
85. Duesberg PH, editor. AIDS: Virus-Or Drug Induced? (Vol. Vol 5). Dordrecht, The Netherlands: Kluwer Academic Publishers (1996).
86. Proctor R. Cancer Wars: How Politics Shapes What We Know and Don't Know About Cancer. New York, NY: Basic Books (1995).
87. Root-Bernstein R. Rethinking AIDS: The Tragic Cost of Premature Consensus. New York, NY: Free Press (1993).
88. Crewdson J. Science Fictions: A Scientific Mystery, a Massive Cover-Up, and the Dark Legacy of Robert Gallo. Boston, MA: Little, Brown and Company (2002).
89. Epstein S. Impure Science: AIDS, Activism and the Politics of Knowledge. Berkeley, CA: University of California Press (1996).
90. Fee E, Brown TM. The past and future of public health practice. Am J Public Health (2000) 90(5):690-1. doi:10.2105/AJPH.90.5.690
91. Branson B, Handsfield H, Lampe M, Janssen R, Taylor A, Lyss S, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR (2006) 55(RR14):1-17.
92. Hirnschall G, Harries A, Easterbrook P, Doherty M, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc (2013) 16:1-7. doi:10.7448/IAS.16.1.18757
93. The HJ Kaiser Family Foundation. Fact Sheet: State Medicaid Coverage of Routine HIV Screening. [Internet]. Available from: http://kff.org/hivaids/fact-sheet/state-medicaid-coverage-of-routinehiv-screening/
94. The White House Office of National AIDS Policy. National HIV/AIDS Strategy for the United States. [Internet]. Available from: www.whitehouse.gov/onap
95. Buchanan DR. An Ethic for Health Promotion: Rethinking the Sources of Human Well-Being. New York, NY: Oxford University Press (2000).
96. Jones JH. Bad Blood: The Tuskegee Syphilis Experiment. New and Expanded Edition. New York: The Free Press (1993).